BACKGROUND: @entity6817 reduce risk from coronary artery bypass graft (CABG) surgery, but the influence of @entity7774 -converting enzyme inhibitors, alpha-2 adrenergic agonists, @entity460 channel blockers and beta-blockers is less clear. OBJECTIVES: We investigated the association of each of these drugs with perioperative risk, accounting for different confounders, and evaluated the class, dose-response and long-term protective effect of @entity6817 . DESIGN: A retrospective analysis of observational data. SETTING: United Kingdom. @entity1 : Sixteen thousand one hundred and ninety-two @entity1 who underwent CABG surgery during the period 01 January 2004 to 31 December 2013 and contributed data to Primary Care Clinical Practice Research Datalink. EXPOSURE VARIABLES: Cardiovascular drugs. OUTCOME MEASURE: Perioperative mortality within 30 days of surgery. STATISTICAL ANALYSIS: Five multivariable logistic regression models and a further Cox regression model were used to account for preexisting cardiovascular and other comorbidities along with lifestyle factors such as BMI, smoking and @entity285 use. RESULTS: Exposure to @entity6817 was most prevalent (85.1% of @entity1 ), followed by beta-blockers (72.8%), angiotensin-converting enzyme inhibitors (60.5%), @entity460 channel blockers (42.8%) and alpha-2 adrenergic agonists (1.2%). The mortality rate was 0.8% in @entity1 not prescribed @entity6817 and 0.4% in those on @entity6817 . @entity6817 were associated with a statistically significant reduced perioperative mortality in all five logistic regression models with adjusted odds ratios (OR) (95% confidence interval, 95% CI) ranging from 0.26 (0.13 to 0.54) to 0.35 (0.18 to 0.67). Cox regression for perioperative mortality [adjusted hazard ratio (95% CI) 0.40 (0.20 to 0.80)] and 6-month mortality [adjusted hazard ratio (95% CI) 0.63 (0.42 to 0.92)] produced similar results. Of the @entity6817 doses tested, only @entity3413 40mg exerted protective effects. The other cardiovascular drugs lacked consistent effects across models. CONCLUSION: @entity6817 appear consistently protective against perioperative mortality from CABG surgery in multiple models, an effect not shared by the other cardiovascular drugs. Further data are needed on whether @entity6817 exert class and dose-response effects.

Effects of five preoperative cardiovascular drugs on mortality after coronary artery bypass surgery: A retrospective analysis of an observational study of 16192 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin'] @entity7774 :: ('MESH:D000809', 'Chemical') :: ['angiotensin'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity285 :: ('D000431', 'Chemical') :: ['alcohol'] @entity6817 :: ('D019821', 'Chemical') :: ['statin', 'Statins', 'statins']
@entity1 :: (9606,Species) :: ['patients']
